Medtronic Plc. · NYSE:MDT
Medtronic — Merger or Acquisition (October 2022)
7 slides from Medtronic's merger presentation, Oct 24, 2022
Slide 1: Intent to separate combined Patient Monitoring and Respiratory Interventions businesses
Intent to separate combined Patient Monitoring and Respiratory Interventions businesses Investor and Analyst Presentation October 24, 2022
Slide 2: Forward looking statements
Forward looking statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are, or may be dee
Slide 3: Separating combined Patient Monitoring and Respiratory Interventions ("NewCo")
Separating combined Patient Monitoring and Respiratory Interventions (“NewCo”) Expected to better position both Medtronic and NewCo for long-term success and value creation Enables Medtronic greater investment focus in the areas of highest strategic priority across the company • A more streamlined p
Slide 4: NewCo's solutions reduce acute care complications, manage respiratory failure, and deliver actionable insights
NewCo’s solutions reduce acute care complications, manage respiratory failure, and deliver actionable insights Respiratory Therapies & Monitoring Puritan BennettTM Ventilators, MicrostreamTM Capnography, McGRATHTM Video Laryngoscope, Shiley™ Airway Protection, ✓ Improve patient safety DARTM Breathin
Slide 5: NewCo's advanced connected care roadmap uniquely positioned to lead category
NewCo’s advanced connected care roadmap uniquely positioned to lead category ICU/NICU OR PACU MED SURG GCF ASC HOME Sense Collect Pulse oximetry and advanced parameters Sensor interface and local display Real-time monitoring Smart capabilities Through actionable and visualization insights able to de
Slide 6: Enhancing both Medtronic and NewCo's strategic and operational focus
Enhancing both Medtronic and NewCo’s strategic and operational focus FY22 Revenue Scale By Segment Highlights Diabetes • Focused portfolio of leading medical device 8% therapies Cardio- • Expanded WAMGR Pro Forma MDT ~$29.4B FY22 Revenue Neuro- Science 30% vascular 39% • Modestly higher revenue grow
Slide 7: Additional details on proposed separation
Additional details on proposed separation Structure / Timing • Intend to pursue separation via a tax-free distribution with completion in next 12-18 months Conditions / Approvals subject to the satisfaction of closing conditions, including: • Obtaining final approval from the Medtronic Board of Dire